Alexion

positive negative up down good bad mixed
Biotech

AstraZeneca’s Strensiq successor misses ph. 3 rare disease goal

The failure of the rare metabolic disease prospect raises doubts about the company’s ability to expand beyond the children served by its existing drug.
Nick Paul Taylor Mar 31, 2026 5:35am
Graphic image of an arrow nailing the bullseye of a target

AstraZeneca's blockbuster contender hits phase 3 gMG goals

Jul 24, 2025 6:20am
Goal disorientation and lack of vision

AstraZeneca amyloidosis drug fails to reduce mortality in ph. 3

Jul 16, 2025 4:28am
money scales
Favicon Fierce Pharma

Syntimmune shareholders win again over AZ, this time for $181M

Jun 12, 2025 11:40am
pivot change turnaround direction walk away

AstraZeneca CEO defends 'fantastic' Alexion buy as halts drug

Feb 6, 2025 6:45am
scrapheap

AZ licenses discarded rare disease drug to Monopar Therapeutics

Oct 24, 2024 2:54pm